Infection and cyclosporine.

Area of Science:

• Immunology
• Pharmacology
• Transplantation Medicine

Background:

• Cyclosporine is a vital immunosuppressive drug impacting T cell function.
• Understanding its clinical effects and risks is essential due to its widespread use.
• While possessing some antimicrobial properties, these are generally clinically insignificant.

Purpose of the Study:

• To review the clinical relevance of cyclosporine's activity and effects.
• To assess the incidence of infection in patients treated with cyclosporine.
• To highlight potential interactions between antimicrobial therapies and cyclosporine.

Main Methods:

• Review of controlled and noncontrolled studies on cyclosporine use.
• Analysis of infection rates in autoimmune disease patients and transplant recipients.
• Evaluation of the impact of antimicrobial therapy on cyclosporine levels and toxicity.

Main Results:

• Infection is infrequent in autoimmune patients on low-dose cyclosporine.
• Cyclosporine use in transplantation may not increase, and could decrease, infection incidence versus standard immunosuppression.
• Fungal, viral, and bacterial infections remain significant causes of morbidity in transplant patients.
• Antimicrobial agents can alter cyclosporine levels, potentially leading to nephrotoxicity or graft rejection.

Conclusions:

• Cyclosporine is generally safe regarding infection risk in autoimmune diseases.
• In transplantation, cyclosporine's infection profile is comparable or favorable to standard immunosuppression.
• Vigilant monitoring of cyclosporine levels is critical when co-administered with antimicrobial therapies to prevent adverse events.